Literature DB >> 8285817

Aldicarb poisoning. A case report with prolonged cholinesterase inhibition and improvement after pralidoxime therapy.

J L Burgess1, J N Bernstein, K Hurlbut.   

Abstract

Aldicarb is the most potent of the commercially available carbamate pesticides and is an unusual source of acute human poisonings. We present the case of a 43-year-old man exposed to aldicarb who developed severe cholinergic symptoms and progressive weakness requiring intubation for 5 days. Both his red blood cell cholinesterase and plasma pseudocholinesterase levels were depressed for a minimum of 44 hours. He demonstrated neuromuscular improvement concurrent with pralidoxime administration. The pertinent medical literature on aldicarb poisoning is reviewed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8285817     DOI: 10.1001/archinte.154.2.221

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Aldicarb-related suicide attempt cases in North of France (2012-2021).

Authors:  Marie Lenski; Agnès Letrillart; Alexandr Gish; Patrick Nisse; Jean-Michel Gaulier; Delphine Allorge
Journal:  Toxicol Res (Camb)       Date:  2022-05-31       Impact factor: 2.680

2.  Cholinergic crisis after rodenticide poisoning.

Authors:  Muhammad Waseem; Christopher Perry; Scott Bomann; Meena Pai; Joel Gernsheimer
Journal:  West J Emerg Med       Date:  2010-12

Review 3.  Biomarkers of human exposure to pesticides.

Authors:  W A Anwar
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

4.  The novel nematicide wact-86 interacts with aldicarb to kill nematodes.

Authors:  Andrew R Burns; Rachel Bagg; May Yeo; Genna M Luciani; Michael Schertzberg; Andy G Fraser; Peter J Roy
Journal:  PLoS Negl Trop Dis       Date:  2017-04-05

5.  Organoleptic assessment and median lethal dose determination of oral aldicarb in rats.

Authors:  Nathaniel C Rice; Noah A Rauscher; Mark C Moffett; Todd M Myers
Journal:  Ann N Y Acad Sci       Date:  2020-08-05       Impact factor: 6.499

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.